The estimated Net Worth of Heidi Hagen is at least $511 Thousand dollars as of 1 May 2024. Ms. Hagen owns over 3,200 units of Alaunos Therapeutics Inc stock worth over $16,226 and over the last 10 years she sold ZIOP stock worth over $0. In addition, she makes $494,697 as Independent Director at Alaunos Therapeutics Inc.
Heidi has made over 7 trades of the Alaunos Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently she exercised 3,200 units of ZIOP stock worth $2,784 on 1 May 2024.
The largest trade she's ever made was buying 23,770 units of Alaunos Therapeutics Inc stock on 2 September 2021 worth over $41,835. On average, Heidi trades about 2,651 units every 91 days since 2015. As of 1 May 2024 she still owns at least 18,650 units of Alaunos Therapeutics Inc stock.
You can see the complete history of Ms. Hagen stock trades at the bottom of the page.
Heidi M. Hagen serves as Independent Director of the Company. Ms. Hagen has served as a member of our board since June 2019. Ms. Hagen has held the position of a biotechnology and pharmaceutical operations and technology consultant with HH Consulting LLC since October 2012. Since October 2015, Ms. Hagen has served as Co-founder and Advisor for Vineti, Inc., a privately-held company that develops and sells cloud-based software platforms for ordering, manufacturing and delivering personalized medicines. Previously, Ms. Hagen served as interim Chief Commercial Officer at ZappRx, Inc. from January 2015 to June 2015. Prior to that, Ms. Hagen served as Global Chief Operating Officer at Sotio LLC, a biotechnology company developing new therapies for the treatment of cancer and autoimmune diseases using its immunotherapy platform and proprietary cell-based technologies, from March 2013 to April 2014. Prior to joining Sotio, Ms. Hagen was Senior Vice President of Operations at Dendreon Corporation from 2002 to 2012, where she was responsible for, among other duties, manufacturing and supply chain operations. Prior to joining Dendreon, Ms. Hagen spent nearly ten years at Immunex Corporation, where she held several positions in drug development and supply chain and operations management. Ms. Hagen has served on the board of directors of Vericel Inc., a publicly-held company developing advanced cell therapies and specialty biologics for the sports medicine and severe burn care markets, since August 2013, and on the board of directors of Lykan Biosciences LLC, a privately held contract manufacturing company, since June 2019. Ms. Hagen earned her B.S. in cell and molecular biology, M.S. in bioengineering, and MBA at the University of Washington.
As the Independent Director of Alaunos Therapeutics Inc, the total compensation of Heidi Hagen at Alaunos Therapeutics Inc is $494,697. There are 4 executives at Alaunos Therapeutics Inc getting paid more, with Laurence Cooper having the highest compensation of $3,317,570.
Heidi Hagen is 51, she's been the Independent Director of Alaunos Therapeutics Inc since 2019. There are 13 older and 3 younger executives at Alaunos Therapeutics Inc. The oldest executive at Alaunos Therapeutics Inc is J. Kevin Buchi, 65, who is the Director.
Heidi's mailing address filed with the SEC is C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE, MA, 02139.
Over the last 19 years, insiders at Alaunos Therapeutics Inc have traded over $2,792,771 worth of Alaunos Therapeutics Inc stock and bought 7,941,160 units worth $39,823,909 . The most active insiders traders include Randal J Kirk, Randal Jintrexon Corp Kirk, and Lindsay A Md Rosenwald. On average, Alaunos Therapeutics Inc executives and independent directors trade stock every 72 days with the average trade being worth of $152,086. The most recent stock trade was executed by Groot Eleanor De on 22 December 2021, trading 20,132 units of ZIOP stock currently worth $25,568.
Ziopharm Oncology is an immuno-oncology company focused on developing end-to-endcost-effective solutions using its non-viralSleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy with Controlled interleukin 12 (IL-12). The Sleeping Beauty platform genetically modifies T cells with DNA plasmids to express T-cell receptors (TCRs) to target specific antigens in solid tumors and chimeric antigen receptors (CARs) to target CD19 in blood cancers with the Company's 3rd generation T-cell manufacturing process, rapid personalized manufacture (RPM). The Sleeping Beauty platform is being advanced in collaboration with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Eden BioCell. The Company also is developing its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex, as monotherapy and in combination with immune checkpoint inhibitors to treat brain cancer, including in collaboration with Regeneron Pharmaceuticals.
Alaunos Therapeutics Inc executives and other stock owners filed with the SEC include: